Rise of the RNA machines – self-amplification in mRNA vaccine design

Jerome D.G. Comes; Gorben P. Pijlman; Tessy A.H. Hick

doi:10.1016/j.tibtech.2023.05.007

Rise of the RNA machines – self-amplification in mRNA vaccine design

Jerome D.G. Comes, Gorben P. Pijlman^*, Tessy A.H. Hick

^*Corresponding author for this work

Virology (VIR)

Research output: Contribution to journal › Article › Academic › peer-review

36 Citations (Scopus)

Abstract

mRNA vaccines have won the race for early COVID-19 vaccine approval, yet improvements are necessary to retain this leading role in combating infectious diseases. A next generation of self-amplifying mRNAs, also known as replicons, form an ideal vaccine platform. Replicons induce potent humoral and cellular responses with few adverse effects upon a minimal, single-dose immunization. Delivery of replicons is achieved with virus-like replicon particles (VRPs), or in nonviral vehicles such as liposomes or lipid nanoparticles. Here, we discuss innovative advances, including multivalent, mucosal, and therapeutic replicon vaccines, and highlight novelties in replicon design. As soon as essential safety evaluations have been resolved, this promising vaccine concept can transform into a widely applied clinical platform technology taking center stage in pandemic preparedness.

Original language	English
Pages (from-to)	1417-1429
Journal	Trends in Biotechnology
Volume	41
Issue number	11
Early online date	14 Jun 2023
DOIs	https://doi.org/10.1016/j.tibtech.2023.05.007
Publication status	Published - Nov 2023

Keywords

lipid nanoparticles
mRNA
platform technology
replicon
self-amplifying RNA
vaccines

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.tibtech.2023.05.007Licence: CC BY

https://edepot.wur.nl/635299Licence: CC BY

Cite this

@article{a1223510a88c4844ba9edec3df5250b0,

title = "Rise of the RNA machines – self-amplification in mRNA vaccine design",

abstract = "mRNA vaccines have won the race for early COVID-19 vaccine approval, yet improvements are necessary to retain this leading role in combating infectious diseases. A next generation of self-amplifying mRNAs, also known as replicons, form an ideal vaccine platform. Replicons induce potent humoral and cellular responses with few adverse effects upon a minimal, single-dose immunization. Delivery of replicons is achieved with virus-like replicon particles (VRPs), or in nonviral vehicles such as liposomes or lipid nanoparticles. Here, we discuss innovative advances, including multivalent, mucosal, and therapeutic replicon vaccines, and highlight novelties in replicon design. As soon as essential safety evaluations have been resolved, this promising vaccine concept can transform into a widely applied clinical platform technology taking center stage in pandemic preparedness.",

keywords = "lipid nanoparticles, mRNA, platform technology, replicon, self-amplifying RNA, vaccines",

author = "Comes, {Jerome D.G.} and Pijlman, {Gorben P.} and Hick, {Tessy A.H.}",

year = "2023",

month = nov,

doi = "10.1016/j.tibtech.2023.05.007",

language = "English",

volume = "41",

pages = "1417--1429",

journal = "Trends in Biotechnology",

issn = "0167-7799",

publisher = "Elsevier",

number = "11",

}

TY - JOUR

T1 - Rise of the RNA machines – self-amplification in mRNA vaccine design

AU - Comes, Jerome D.G.

AU - Pijlman, Gorben P.

AU - Hick, Tessy A.H.

PY - 2023/11

Y1 - 2023/11

N2 - mRNA vaccines have won the race for early COVID-19 vaccine approval, yet improvements are necessary to retain this leading role in combating infectious diseases. A next generation of self-amplifying mRNAs, also known as replicons, form an ideal vaccine platform. Replicons induce potent humoral and cellular responses with few adverse effects upon a minimal, single-dose immunization. Delivery of replicons is achieved with virus-like replicon particles (VRPs), or in nonviral vehicles such as liposomes or lipid nanoparticles. Here, we discuss innovative advances, including multivalent, mucosal, and therapeutic replicon vaccines, and highlight novelties in replicon design. As soon as essential safety evaluations have been resolved, this promising vaccine concept can transform into a widely applied clinical platform technology taking center stage in pandemic preparedness.

AB - mRNA vaccines have won the race for early COVID-19 vaccine approval, yet improvements are necessary to retain this leading role in combating infectious diseases. A next generation of self-amplifying mRNAs, also known as replicons, form an ideal vaccine platform. Replicons induce potent humoral and cellular responses with few adverse effects upon a minimal, single-dose immunization. Delivery of replicons is achieved with virus-like replicon particles (VRPs), or in nonviral vehicles such as liposomes or lipid nanoparticles. Here, we discuss innovative advances, including multivalent, mucosal, and therapeutic replicon vaccines, and highlight novelties in replicon design. As soon as essential safety evaluations have been resolved, this promising vaccine concept can transform into a widely applied clinical platform technology taking center stage in pandemic preparedness.

KW - lipid nanoparticles

KW - mRNA

KW - platform technology

KW - replicon

KW - self-amplifying RNA

KW - vaccines

U2 - 10.1016/j.tibtech.2023.05.007

DO - 10.1016/j.tibtech.2023.05.007

M3 - Article

C2 - 37328401

AN - SCOPUS:85162924840

SN - 0167-7799

VL - 41

SP - 1417

EP - 1429

JO - Trends in Biotechnology

JF - Trends in Biotechnology

IS - 11

ER -

Rise of the RNA machines – self-amplification in mRNA vaccine design

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this